

November 13, 2020

News Release

Company: Olympus Corporation  
Yasuo Takeuchi, Director, Representative Executive Officer, President and CEO  
(Code: 7733, First Section, Tokyo Stock Exchange)  
Contact: Takaaki Sakurai, Vice President, Investor Relations  
TEL: +81-3-3340-2111

## Notice Concerning the Commencement of Deliberation on Reorganization of Domestic Sales Functions of the Olympus Group

Olympus Corporation ("Olympus") hereby announces to commence deliberation on the reorganization of the Olympus Group's domestic sales functions as follows:

### 1. Background and Purpose of this Deliberation

Olympus has announced, on November 6, 2019, its new corporate strategy ("Corporate Strategy") to achieve growth as a global medical technology ("medtech") company, in order to realize sustainable growth for the Olympus Group overall. Under this Corporate Strategy, Olympus's strategic aspiration is to grow into a globally-leading medtech company contributing to people's lives by delivering innovative solutions that benefit patients, healthcare professionals, payors, and providers.

In particular, the business environment surrounding the Olympus Group's domestic market is undergoing extensive change due to, amongst others, demographic changes, expansion of client needs demanding comprehensive value-added solutions, and intensifying competition. To achieve the sustainable growth in such environment, Olympus needs to implement necessary steps to reform its sales function. Currently the Olympus Group's domestic sales function is separately handled by Olympus and Olympus Medical Science Sales Co., Ltd., a wholly-owned subsidiary of Olympus. By integrating the sales functions in these two companies, Olympus aims to: realize flexible resource assignment, enhance cooperation with business partners, implement unified sales policy across Japan, and retain highly capable talent; and as a result strengthen its sales function.

### 2. Future Outlook

The reorganization of the Olympus Group's domestic sales functions is scheduled to occur on October 1, 2021. Olympus will make further announcement once the details are decided. As this is an internal reorganization, Olympus does not consider there will be any significant impact on its consolidated financial results.